Skip to Content

Baricitinib May Shorten Recovery Time in Hospitalized COVID-19 Patients

MONDAY, Sept. 14, 2020 -- Using an anti-inflammatory medicine along with the antiviral drug remdesivir appears to shorten COVID-19 patients' recovery time, according to drug company Eli Lilly.

Remdesivir -- from Gilead Sciences -- has previously been shown to reduce recovery time to an average of four days. Patients who also received Lilly's anti-inflammatory drug baricitinib (sold as Olumiant to treat rheumatoid arthritis) recovered one day sooner than those who took remdesivir alone, according to the company, the Associated Press reported. Recovery is defined as being well enough to leave the hospital.

The findings from the 1,000-person study, sponsored by the U.S. National Institute of Allergy and Infectious Diseases, were released Monday. The study has not been published or reviewed by independent scientists, but U.S. health officials said Lilly's statement about the results was accurate, the AP reported.

The possible emergency use of baricitinib for hospitalized COVID-19 patients will be discussed with U.S. regulators, Lilly said.

AP News Article

© 2020 HealthDay. All rights reserved.

Posted: September 2020

Read this next

More Than Half of Pregnant Women With COVID-19 Asymptomatic

FRIDAY, Sept. 18, 2020 -- More than half of hospitalized pregnant women with COVID-19 are asymptomatic at admission, while pregnant women hospitalized for COVID-19-related illness have...

Lower Proportion of Inpatients With COVID-19 Wear Glasses

FRIDAY, Sept. 18, 2020 -- The proportion of inpatients with COVID-19 who wear eyeglasses for extended daily periods is lower than in the general population, according to a study published...

Older Adults Experiencing More Loneliness During Pandemic

FRIDAY, Sept. 18, 2020 -- Older adults are feeling more isolated during the COVID-19 pandemic, according to a report published online Sept. 14 based on the results of the University...